Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
CBX-12 · 1 trial · 12 indications
NCI CTCAE v5.0
Safety Review Committee Analysis of Safety and PK Data
Safety Review Committee Analysis of Safety and PK Data
Safety Review Committee Analysis of Safety and PK Data
ORR Based on RECIST v1.1
| Arm | Type | Description |
|---|---|---|
| Phase 1 Schedule B Dose Escalation (Daily Dosing x 3) | EXPERIMENTAL | CBX-12 administered on a daily x 3, 3 week schedule |
| Phase 1 Schedule C Dose Escalation (Once Weekly Dosing ) | EXPERIMENTAL | CBX-12 administered once weekly, 4 week schedule |
| Phase 2 Ovarian Cancer Expansion Cohort | EXPERIMENTAL | CBX-12 administered TBD |
| Phase 2 Metastatic Breast Expansion Cohort | EXPERIMENTAL | CBX-12 administered TBD |
| Phase 1 Schedule A Dose Escalation (Daily Dosing x 5) | EXPERIMENTAL | CBX-12 administered on a daily x 5, 3 week schedule |
| Phase 1 Modified Schedule B Dose Escalation (Once Every 3 weeks) | EXPERIMENTAL | CBX-12 administered once every 3 weeks |
| Name | Type | Description |
|---|---|---|
| CBX-12 | DRUG | CBX-12 is an alphalex construct which consists of a low-pH insertion peptide, a self-immolating linker, and exatecan as the pharmacologically active moiety |
Key Inclusion Criteria: * Subject has a histologically- or cytologically-diagnosed solid tumor which is advanced or metastatic and which has progressed on or following at least one systemic therapy regimen administered for advanced or metastatic disease or for which no approved therapy exists. Subj...